09 Jun Axio BioPharma and Likarda Announce Strategic Partnership to Accelerate Biologic Drug Development and Delivery
Partnership combines AI-powered protein manufacturing with advanced drug delivery technologies to accelerate timelines and improve therapeutic outcomes.
MADISON, Wis. and KANSAS CITY, Mo., June 9, 2025 /PRNewswire/ — Axio BioPharma Inc., a next-generation biomanufacturing company using AI to transform mammalian protein production, and Likarda Inc., a leader in advanced drug delivery and formulation technologies, today announced a strategic partnership to accelerate innovation in biologic drug development. This collaboration will integrate Likarda’s proprietary delivery technologies with Axio’s manufacturing capabilities, creating a more efficient and scalable path to clinical manufacturing for clients across the biopharmaceutical sector.
Through this collaboration, Axio BioPharma will incorporate Likarda’s proprietary delivery platforms— including its Core-Shell Spherification® (CSS®) hydrogel technology for encapsulation, stability, and controlled release —into its service offering, enhancing workflows for monoclonal antibodies (mAbs), bispecifics, and Fc-fusions. Likarda will also offer Axio’s discovery-to-GMP manufacturing capabilities to its client base, supporting programs in need of high-quality protein production and scalable manufacturing solutions.
“This partnership brings delivery innovation directly into the development process, helping our clients move faster and make better decisions,” said Justin Byers, CEO of Axio BioPharma. “By aligning earlier on both delivery and manufacturing, we reduce friction, shorten timelines, and provide integrated solutions that truly support our clients’ goals.”